These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18657036)

  • 41. Antiviral treatment of chronic hepatitis C in clinical routine.
    Maieron A; Metz-Gercek S; Hackl F; Ziachehabi A; Fuchsteiner H; Luger C; Mittermayer H; Schöfl R
    Wien Klin Wochenschr; 2010 Apr; 122(7-8):237-42. PubMed ID: 20503023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy.
    Schiavon LL; Narciso-Schiavon JL; Carvalho-Filho RJ; Sampaio JP; El Batah PN; Silva GA; Carvente CT; Silva AE; Ferraz ML
    Antivir Ther; 2011; 16(3):291-8. PubMed ID: 21555811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience].
    Vergara M; Gallach M; Dalmau B; Gil M; Miquel M; Rudi N; Gavarro A; Cebollero A; Masip M; Real J
    Gastroenterol Hepatol; 2008 May; 31(5):274-9. PubMed ID: 18448055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delivery of treatment for hepatitis C virus infection in the primary care setting.
    Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ
    Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):1003-9. PubMed ID: 25051216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response.
    Mohammed AQ; Auckle R; Li HL; Xu SL; Liu L; Zhao DD; Che WL
    Am J Med Sci; 2018 Jun; 355(6):566-572. PubMed ID: 29891040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues.
    Wu KT; Yang JF; Chuang WL; Yu ML
    J Hepatol; 2010 Feb; 52(2):305; author reply 305-6. PubMed ID: 20006403
    [No Abstract]   [Full Text] [Related]  

  • 47. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
    Doehring A; Hofmann WP; Schlecker C; Zeuzem S; Sarrazin C; Berg T; Müller T; Herrmann E; Geisslinger G; Lötsch J
    Pharmacogenet Genomics; 2011 May; 21(5):289-96. PubMed ID: 21346688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
    Pawłowska M
    Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C.
    Hu JH; Chang ML; Huang TJ; Yeh CT; Chiu WN; Chiang MS; Chen MY
    J Interferon Cytokine Res; 2019 Apr; 39(4):205-213. PubMed ID: 30855203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    Morihara D; Watanabe H; Takata K; Iwashita H; Tsuchiya N; Kunimoto H; Kuno S; Fukunaga A; Yotsumoto K; Tanaka T; Sakurai K; Hirano G; Yokoyama K; Nishizawa S; Yoshikane M; Anan A; Takeyama Y; Kitamura Y; Iwata K; Irie M; Shakado S; Sohda T; Sakisaka S
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):55-64. PubMed ID: 25370853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.
    Hernández A; Domper F; León A; Lorente R; López B; de la Santa E; Cabanillas M; Patón R; Olmedo J; Galván MD; Rodríguez E
    Rev Esp Enferm Dig; 2009 Oct; 101(10):671-9. PubMed ID: 19899935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal therapy in genotype 1 patients.
    Farnik H; Mihm U; Zeuzem S
    Liver Int; 2009 Jan; 29 Suppl 1():23-30. PubMed ID: 19207963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expert opinion on the treatment of patients with chronic hepatitis C.
    Zeuzem S; Berg T; Moeller B; Hinrichsen H; Mauss S; Wedemeyer H; Sarrazin C; Hueppe D; Zehnter E; Manns MP
    J Viral Hepat; 2009 Feb; 16(2):75-90. PubMed ID: 18761607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative efficiency and side effects of combined antiviral therapy of chronic hepatitis C].
    Gromova NI; Bogomolov BP
    Klin Med (Mosk); 2008; 86(9):43-6. PubMed ID: 19048837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.
    Sjogren MH; Sjogren R; Lyons MF; Ryan M; Santoro J; Smith C; Reddy KR; Bonkovsky H; Huntley B; Faris-Young S
    Dig Dis Sci; 2007 Jun; 52(6):1540-7. PubMed ID: 17406822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Results of the treatment of chronic hepatitis C genotype 4--a comparative analysis with genotype 1].
    López-Alonso G; Agreda M; Devesa MJ; Cuenca F; Suárez A; Ortega L; Díaz-Rubio M; Ladero JM
    Rev Esp Enferm Dig; 2008 Apr; 100(4):208-11. PubMed ID: 18563977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.
    Mazzaro C; Panarello G; Mauro E; Gattei V; Pozzato G
    Dig Liver Dis; 2015 Jul; 47(7):613-6. PubMed ID: 25890508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection.
    Vespasiani-Gentilucci U; Galati G; Mazzarelli C; D'Avola D; Spataro S; Gallo P; Rigon A; Pellicelli A; Dicuonzo G; Afeltra A; Picardi A
    J Interferon Cytokine Res; 2011 Feb; 31(2):207-10. PubMed ID: 20874229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COMBINED ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON (PEG-IFN) Α-2A (PEGFERON) AND RIBAVIRIN (COPEGUS) IN INMATES.
    Vashakidze E; Imnadze T
    Georgian Med News; 2017 Mar; (264):86-90. PubMed ID: 28480857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].
    Belkahla N; Kchir H; Maamouri N; Ouerghi H; Hariz FB; Chouaib S; Chaabouni H; Mami NB
    Rev Med Interne; 2010 Nov; 31(11):e1-3. PubMed ID: 20605283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.